TPO and chronic idiopathic urticaria: In the XCUISITE study conducted by Maurer et al. in 2011, the focus was on investigating the efficacy of omalizumab in patients with chronic spontaneous urticaria (CSU) who exhibited IgE autoantibodies against thyroperoxidase (TPO).